Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IntReALL HR 2010
2024-513070-21-00Phase 2Authorised
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Feb 2018
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 13
01
Overview
Phase 2, randomised, open-label trial of bortezomib in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Complete remission 2 rate after randomized induction. Planned start Feb 2018; status: authorised.
02
Drugs
bortezomib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2024-513070-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513070-21-00.